Han Shixun, Fan Haonan, Zhong Guoxuan, Ni Lei, Shi Wenhao, Fang Yushan, Wang Chenliang, Wang Li, Song Lang, Zhao Jianhui, Tang Mei, Yang Bing, Li Li, Bai Xueli, Zhang Qi, Liang Tingbo, Xu Yanhui, Feng Xin-Hua, Ding Chen, Fang Dong, Zhao Bin
MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Cancer Center, Zhejiang University, Hangzhou, China.
Hepatology. 2025 Mar 1;81(3):808-822. doi: 10.1097/HEP.0000000000000875. Epub 2024 Apr 1.
BACKGROUND AND AIMS: Epigenetic reprogramming and escape from terminal differentiation are poorly understood enabling characteristics of liver cancer. Keratin 19 (KRT19), classically known to form the intermediate filament cytoskeleton, is a marker of stemness and worse prognosis in liver cancer. This study aimed to address the functional roles of KRT19 in liver tumorigenesis and to elucidate the underlying mechanisms. APPROACH AND RESULTS: Using multiplexed genome editing of hepatocytes in vivo, we demonstrated that KRT19 promoted liver tumorigenesis in mice. Cell fractionation revealed a previously unrecognized nuclear fraction of KRT19. Tandem affinity purification identified histone deacetylase 1 and REST corepressor 1, components of the corepressor of RE-1 silencing transcription factor (CoREST) complex as KRT19-interacting proteins. KRT19 knockout markedly enhanced histone acetylation levels. Mechanistically, KRT19 promotes CoREST complex formation by enhancing histone deacetylase 1 and REST corepressor 1 interaction, thus increasing the deacetylase activity. ChIP-seq revealed hepatocyte-specific genes, such as hepatocyte nuclear factor 4 alpha ( HNF4A ), as direct targets of KRT19-CoREST. In addition, we identified forkhead box P4 as a direct activator of aberrant KRT19 expression in liver cancer. Furthermore, treatment of primary liver tumors and patient-derived xenografts in mice suggest that KRT19 expression has the potential to predict response to histone deacetylase 1 inhibitors especially in combination with lenvatinib. CONCLUSIONS: Our data show that nuclear KRT19 acts as a transcriptional corepressor through promoting the deacetylase activity of the CoREST complex, resulting in dedifferentiation of liver cancer. These findings reveal a previously unrecognized function of KRT19 in directly shaping the epigenetic landscape in cancer.
背景与目的:表观遗传重编程以及从终末分化中逃逸是肝癌尚未被充分理解的促成特征。角蛋白19(KRT19),传统上认为其构成中间丝细胞骨架,是肝癌干性和预后较差的标志物。本研究旨在探讨KRT19在肝脏肿瘤发生中的功能作用,并阐明其潜在机制。 方法与结果:利用体内肝细胞的多重基因组编辑,我们证明KRT19促进小鼠肝脏肿瘤发生。细胞分级分离揭示了KRT19一个先前未被识别的核部分。串联亲和纯化鉴定出组蛋白去乙酰化酶1和RE-1沉默转录因子(CoREST)复合物共抑制因子的组成成分REST共抑制因子1作为与KRT19相互作用的蛋白。KRT19基因敲除显著提高组蛋白乙酰化水平。机制上,KRT19通过增强组蛋白去乙酰化酶1和REST共抑制因子1的相互作用促进CoREST复合物形成,从而增加去乙酰化酶活性。染色质免疫沉淀测序(ChIP-seq)揭示肝细胞特异性基因,如肝细胞核因子4α(HNF4A),是KRT19-CoREST的直接靶点。此外,我们确定叉头框P4是肝癌中异常KRT19表达的直接激活因子。此外,对小鼠原发性肝肿瘤和患者来源异种移植物的治疗表明,KRT19表达有可能预测对组蛋白去乙酰化酶1抑制剂的反应,特别是与乐伐替尼联合使用时。 结论:我们的数据表明,核KRT19通过促进CoREST复合物的去乙酰化酶活性作为转录共抑制因子,导致肝癌去分化。这些发现揭示了KRT19在直接塑造癌症表观遗传格局方面以前未被认识的功能。
Cell Mol Gastroenterol Hepatol. 2025